Regeneron Pharmaceuticals Officer Files Form 144 to Sell $3.79M in Common Stock

Executive Summary

On November 4, 2026, Jason Pitofsky, an Officer of Regeneron Pharmaceuticals, Inc. ($REGN), filed a Form 144 notice covering the proposed sale of 3,883 shares of common stock with an aggregate market value of approximately $3,789,808.

Transaction Details

• Filing Date: November 4, 2026
• Approximate Sale Date: November 4, 2026
• Securities Class: Common stock
• Number of Shares: 3,883
• Aggregate Market Value: $3,789,808 (~$976.00 per share)
• Shares Outstanding: 101,630,713
• Broker: UBS Financial Services Inc
• Execution Venue: NASDAQ

Origin of Securities

The shares being offered were acquired through stock option grants and cashless exercise on November 4, 2026:

• 905 shares: Option granted on December 9, 2020
• 1,478 shares: Option granted on December 8, 2021
• 1,500 shares: Option granted on December 16, 2022

Market Impact & Significance

The proposed transaction represents less than 0.01% of Regeneron's 101.6 million outstanding shares. Because these sales stem from routine cashless option exercises of equity compensation granted between 2020 and 2022, the trading significance is categorized as Low and reflects standard executive compensation liquidity rather than a directional signal on business performance.